Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
- PMID: 31076382
- PMCID: PMC6992839
- DOI: 10.1016/S2213-2600(19)30136-5
Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
Erratum in
-
Correction to Lancet Respir Med 2019; published online May 7. http://dx.doi.org/10.1016/S2213-2600(19)30136-5.Lancet Respir Med. 2019 Jul;7(7):e22. doi: 10.1016/S2213-2600(19)30202-4. Lancet Respir Med. 2019. PMID: 31253379 No abstract available.
Conflict of interest statement
Conflicts of Interest
CDB receives consulting fees from Medial EarlySign, LLC and GRAIL, Inc. All other authors report no conflicts of interest.
Figures
References
-
- The ASCO Post. WCLC 2018: NELSON Study: CT Screening for Early Lung Cancer Reduces Lung Cancer Mortality. 2018.
-
- Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol 2017;18(12):e754–66. - PubMed
-
- Ruano-Ravina A, Pérez-Ríos M, Casàn-Clará P, Provencio-Pulla M. Low-dose CT for lung cancer screening. Lancet Oncol 2018;19(3):e131–2. - PubMed
